BBT-877 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia2

85. Idiopathic interstitial pneumonia


Clinical trials : 627 Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05483907
(ClinicalTrials.gov)
February 21, 202327/7/2022To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPFA Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: BBT-877;Drug: PlaceboBridge Biotherapeutics, Inc.NULLRecruiting40 YearsN/AAll120Phase 2United States;Australia;Israel
2NCT03830125
(ClinicalTrials.gov)
February 13, 201931/1/2019Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy SubjectsA Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult SubjectsIdiopathic Pulmonary FibrosisDrug: BBT-877, Single dose;Drug: Placebo group;Drug: BBT-877, Multiple dosesBridge Biotherapeutics, Inc.KCRN Research, LLCCompleted19 Years55 YearsAll88Phase 1United States